Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday. They currently have a $6.00 price objective on the biotechnology company’s stock.

Other research analysts have also issued reports about the company. Roth Capital reissued a “buy” rating and issued a $6.00 price target on shares of Actinium Pharmaceuticals in a research report on Monday. Maxim Group began coverage on Actinium Pharmaceuticals in a research report on Thursday, September 14th. They issued a “buy” rating and a $3.00 price target for the company.

Shares of Actinium Pharmaceuticals (ATNM) traded down 0.69% during trading on Monday, hitting $0.72. The stock had a trading volume of 1,264,484 shares. Actinium Pharmaceuticals has a 12 month low of $0.54 and a 12 month high of $1.72. The company’s market cap is $57.61 million. The stock has a 50-day moving average price of $0.65 and a 200 day moving average price of $1.01.

ILLEGAL ACTIVITY NOTICE: “Actinium Pharmaceuticals’ (ATNM) Buy Rating Reiterated at HC Wainwright” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at

A hedge fund recently raised its stake in Actinium Pharmaceuticals stock. Vanguard Group Inc. raised its position in shares of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) by 7.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,143,745 shares of the biotechnology company’s stock after purchasing an additional 148,579 shares during the quarter. Vanguard Group Inc. owned 3.67% of Actinium Pharmaceuticals worth $2,616,000 at the end of the most recent reporting period.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc and related companies with's FREE daily email newsletter.